3SBio Inc
HKEX:1530
3SBio Inc
Net Income (Common)
3SBio Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
3SBio Inc
HKEX:1530
|
Net Income (Common)
¥1.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-¥13.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
-¥1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
¥1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
¥8.5B
|
CAGR 3-Years
40%
|
CAGR 5-Years
47%
|
CAGR 10-Years
45%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Income (Common)
¥1.3B
|
CAGR 3-Years
61%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
See Also
What is 3SBio Inc's Net Income (Common)?
Net Income (Common)
1.5B
CNY
Based on the financial report for Dec 31, 2023, 3SBio Inc's Net Income (Common) amounts to 1.5B CNY.
What is 3SBio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
4%
Over the last year, the Net Income (Common) growth was -19%. The average annual Net Income (Common) growth rates for 3SBio Inc have been 23% over the past three years , 4% over the past five years .